MediWound Stock Forecast, Price & News

MediWound (NASDAQ:MDWD) Frequently Asked Questions

Is MediWound a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MediWound stock.
View analyst ratings for MediWound or view top-rated stocks.

What stocks does MarketBeat like better than MediWound?

Wall Street analysts have given MediWound a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MediWound wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MediWound's next earnings date?

MediWound is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for MediWound.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) posted its quarterly earnings results on Tuesday, August, 10th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.01. MediWound had a negative net margin of 38.43% and a negative trailing twelve-month return on equity of 171.14%.
View MediWound's earnings history.

How has MediWound's stock been impacted by COVID-19 (Coronavirus)?

MediWound's stock was trading at $2.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MDWD shares have increased by 51.1% and is now trading at $3.49.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MDWD?

3 analysts have issued twelve-month price objectives for MediWound's shares. Their forecasts range from $6.50 to $9.00. On average, they expect MediWound's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 114.9% from the stock's current price.
View analysts' price targets for MediWound or view top-rated stocks among Wall Street analysts.

Who are MediWound's key executives?

MediWound's management team includes the following people:

• Sharon Malka, Chief Executive Officer
• Boaz Gur-Lavie, Chief Financial Officer
• Lior Rosenberg, Chief Medical Officer
• Ety Klinger, Chief Research & Development Officer
• Roni Solomon, Vice President-Finance

Who are some of MediWound's key competitors?

Some companies that are related to MediWound include HEXO (HEXO), Natural Alternatives International (NAII), FitLife Brands (FTLF), Grove (GRVI), Bon Natural Life (BON), Mannatech (MTEX), Charlie's (CHUC), Charlie's (CHUCD), Glucose Health (GLUC), Happiness Biotech Group (HAPP), Nutra Pharma (NPHC), General Cannabis (CANN), Tauriga Sciences (TAUG), Exactus (EXDI) and GLG Life Tech (GLGLF).
View all of MDWD's competitors.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), The Blackstone Group (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

What is MediWound's stock symbol?

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

Who are MediWound's major shareholders?

MediWound's stock is owned by many different retail and institutional investors. Top institutional shareholders include Migdal Insurance & Financial Holdings Ltd. (4.39%), Renaissance Technologies LLC (1.74%), Sargent Investment Group LLC (1.23%), Morgan Stanley (0.28%), Morgan Stanley (0.28%) and JPMorgan Chase & Co. (0.24%).

Which major investors are selling MediWound stock?

MDWD stock was sold by a variety of institutional investors in the last quarter, including Migdal Insurance & Financial Holdings Ltd., Renaissance Technologies LLC, Sargent Investment Group LLC, and Creative Planning.

Which major investors are buying MediWound stock?

MDWD stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., Meitav Dash Investments Ltd., Meitav Dash Investments Ltd., Toroso Investments LLC, Squarepoint Ops LLC, and PDT Partners LLC.

How do I buy shares of MediWound?

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediWound's stock price today?

One share of MDWD stock can currently be purchased for approximately $3.49.

How much money does MediWound make?

MediWound has a market capitalization of $95.06 million and generates $21.76 million in revenue each year. The biopharmaceutical company earns $-9,200,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does MediWound have?

MediWound employs 75 workers across the globe.

What is MediWound's official website?

The official website for MediWound is www.mediwound.com.

Where are MediWound's headquarters?

MediWound is headquartered at 42 HAYARKON STREET, YAVNE L3, 8122745.

How can I contact MediWound?

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972779714100 or via email at [email protected].